RemedyRepack Rifampin Capsules Recall: Failed Impurities Risk
RemedyRepack Inc. recalls 300 mg Rifampin Capsules due to failed impurities and degradation specifications. This Rx-only medication may pose risks if not used properly.
Lower-risk recall
Failed Impurities/Degradation specifications
Contact the company
What happened, in plain English
RemedyRepack Inc. is recalling 300 mg Rifampin Capsules (30-count blister packs) because they failed impurities and degradation tests. This could lead to unsafe drug levels if taken as prescribed. Read more at govinfonow.com/recall/34173-remedyrepack-rifampin-capsules-recall-failed-impurities-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/34173-remedyrepack-rifampin-capsules-recall-failed-impurities-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0098-2023
Cite this page
“RemedyRepack Rifampin Capsules Recall: Failed Impurities Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34173-remedyrepack-rifampin-capsules-recall-failed-impurities-risk. Based on FDA recall #D-0098-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0098-2023%22&limit=1).
Why it’s dangerous
The capsules failed impurities and degradation specifications, meaning they might not contain the correct drug levels. This could cause treatment failure or side effects if taken as directed.
Who’s affected
Prescription patients who received these specific Rifampin Capsules from RemedyRepack Inc. are affected. Patients on long-term antibiotic treatment are most at risk due to potential medication inefficacy.
How to tell if you have this one
Check for the 300 mg Rifampin Capsules in 30-count blister packs with the Repackaged NDC 70518-2404-00. The lot numbers J0599794-022322 (exp. 02/28/2023) and J0621369-052622 (exp. 06/30/2023) are also identifiers.
- Brand
RemedyRepack- Category
Drug
What to do — step by step
Check Medication Details
Verify the product label for the Repackaged NDC 70518-2404-00 and lot numbers J0599794-022322 or J0621369-052622.
Where it went and when
Where it was distributed
Distributed in Pennsylvania.
FDA distribution: “Product was distributed to one account in PA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Pennsylvania.
Recall timeline
FDA terminated this recall 2 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
What should I do if I have these capsules?
Check the product label for the Repackaged NDC 70518-2404-00 and lot numbers to confirm if it's affected. No specific action is required beyond verification.
Is this a safety hazard?
This recall is for medication efficacy, not immediate safety risks. The hazard is low risk as it relates to treatment effectiveness, not physical harm.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0098-2023 (December 20, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0098-2023 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.